HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Single-Wholesaler Model Has No Merits for Hospitals: Hyogo Doctors Group
September 7, 2023
-
REGULATORY Japan Eyes AI-Driven Drug Discovery Project for Cancer, Intractable Diseases
September 7, 2023
-
BUSINESS Osaka Court Bars Sawai’s Teribone Generic over Manufacturing Patents
September 6, 2023
-
BUSINESS Santen to Run Voluntary Redundancy Program Targeting Age 50 and Up
September 5, 2023
-
REGULATORY Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
-
REGULATORY MHLW Must Streamline Operations via DX, Improve Staff’s Work-Life Balance: Official
September 1, 2023
-
REGULATORY Chuikyo Payer Rep Floats Deferred Price Cuts for PMP upon Generic Entries
August 31, 2023
-
BUSINESS Novartis Rolls Out Luxturna in Japan, 2 Treatment Facilities Selected
August 31, 2023
-
REGULATORY MHLW Top Pharma Officer Remains Committed to Fast, Safe Access to Good Drugs
August 31, 2023
-
REGULATORY Medical DX Office to Kick Off in September, Explore Better Use of Medical Data for Drug Discovery
August 30, 2023
-
BUSINESS First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
August 30, 2023
-
ORGANIZATION JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
August 29, 2023
-
REGULATORY Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
August 29, 2023
-
REGULATORY Japan to Shell Out Up to 30 Billion Yen for National Project to Spur Dementia R&D
August 28, 2023
-
REGULATORY MHLW Eyes Pediatric, Orphan Drug Advisory Team within PMDA: FY2024 Budget Request
August 25, 2023
-
ACADEMIA Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
August 25, 2023
-
REGULATORY Drug Pricing Organization Proposes Changes in PMP, Re-Pricing Criteria towards 2024 Reform
August 24, 2023
-
REGULATORY Chuikyo OKs Listing of Litfulo and More; 10 Billion-Plus Yen Peak Sales for Pfizer, Sobi Meds
August 24, 2023
-
REGULATORY Luxturna Priced at 49.6 Million Yen per Vial, Peak Sales Put at 500 Million Yen with 5 Patients
August 24, 2023
-
REGULATORY Hemlibra, Lynparza, Zejula Face Quarterly Re-Pricing, 7.7-10.2% Cut in November
August 24, 2023
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
